Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.49 |
| ▸ | ITGAV | P06756 | 20/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 15/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.45 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.45 |
| ▸ | ITGA8 | P53708 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744706 | 0.88 | ITGB3 (0.56) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6840645 | 0.85 | ITGB3 (0.68) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6738389 | 0.82 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7470007 | 0.80 | ITGB3 (0.46) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6841294 | 0.80 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7452540 | 0.80 | ITGB3 (0.44) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6888885 | 0.80 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL244092 | 0.77 | ITGB3 (0.68) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6886353 | 0.74 | ITGB3 (0.51) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6744701 | 0.73 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | G. D. SEARLE & CO. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6689754-B1 | PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| EP-1070060-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. Searle & Co. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | ITGB3, ITGAL, ITGB1 | ITGB3 1/4885ITGAV 5/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.